Nadia Laack, MD MS

414 posts

Nadia Laack, MD MS banner
Nadia Laack, MD MS

Nadia Laack, MD MS

@n_laack

Professor and Chair, Department of Radiation Oncology. @MayoRadOnc Opinions stated are my own. Like/RT ≠ endorsement

Mayo Cinic Katılım Kasım 2013
262 Takip Edilen1.1K Takipçiler
Nadia Laack, MD MS retweetledi
gelareh-zadeh
gelareh-zadeh@gelarehzadeh·
Today’s collaboration announcement between @MayoClinic and @Merck matters to me because it reflects how we’re rethinking drug discovery and precision medicine. @MayoClinicPlatform
Mayo Clinic@MayoClinic

Today, Mayo Clinic and @Merck announced a research and development collaboration to advance AI-enabled drug discovery and precision medicine, accelerating discoveries that improve care for patients worldwide. The collaboration leverages Mayo Clinic Platform to integrate global clinical expertise, multimodal data and advanced analytics to support early-stage drug discovery and development. Initial areas of focus include neurology, gastroenterology and dermatology. The agreement positions Mayo Clinic as a global leader in platform-based collaboration, applying AI and clinical insight to advance precision medicine and strengthen the path from discovery to patient care. Learn more: mayocl.in/4c6Pymd

English
0
2
22
2.6K
Nadia Laack, MD MS retweetledi
Yasamin Sharifzadeh
Yasamin Sharifzadeh@yazshaz·
Come to @ACRORadOnc to see more of my flight attendant outfits 😆 …and to learn about HCC with legendary @ldawsonmd !!!
ACRO - American College of Radiation Oncology@ACRORadOnc

Dr. @yazshaz has a preview of the #ACRO2026 GI session with @ldawsonmd from @UofTDRO! Don't miss this talk on hepatocellular carcinoma -- register at acro.org/annualmeeting & we'll see you in FL in February. #RadiatingExcellence @ACROresident @RadoncROVER @S_W_R_O @QuadShotNews

English
0
1
7
613
Nadia Laack, MD MS
Nadia Laack, MD MS@n_laack·
Congratulations to our AI team for winning TWO #VIBEsummit awards for their work developing tools detect prostate cancer recurrence and reduce provider burden with automated daily summaries and trial matching. So proud of this incredible team! @MayoRadOnc @MayoCancerCare
Nadia Laack, MD MS tweet media
English
1
2
16
562
Nadia Laack, MD MS
Nadia Laack, MD MS@n_laack·
Of 3300 physicians and scientists, Dr Paul Brown, my colleague and mentor, was recognized as one of three clinicians of the year at Mayo Clinic Rochester 400+ publications, 4-time teacher of the year, mentor to countless trainees, and dedicated and compassionate clinician
Nadia Laack, MD MS tweet media
English
4
9
50
2.1K
Nadia Laack, MD MS
Nadia Laack, MD MS@n_laack·
Our own Dr Sharifzadeh’s work on direct-to-unit simulation and adaptive SBRT highlighted in the ASTRO news today. Excellent local control and outcomes while improving access for those at a distance from radiation care ⁦@MayoRadOnc⁩ ⁦@MayoCancerCare⁩
Nadia Laack, MD MS tweet media
English
0
5
26
3K
Nadia Laack, MD MS retweetledi
Daniel E Spratt
Daniel E Spratt@DrSpratticus·
#ASTRO25 SCAROP meeting. Good turnout. Interesting lineup from most junior as Chair to most senior. A number of chairs >15 years and counting. Nice to hear from some of the innovators and those helping push field forward. Too many to tag
Daniel E Spratt tweet media
English
0
7
49
2.9K
Nadia Laack, MD MS retweetledi
Stanislav (Stas) Lazarev, MD
Stanislav (Stas) Lazarev, MD@StasLazarev·
👏 Outstanding, balanced review by @MartinTomMD calling out #Vorasidenib hype in INDIGO (RCT of Vorasidenib vs Placebo for low grade glioma (LGG) patients with gross disease (i.e. high-risk LGG) INDIGO data (IDH-mut LGG): ▶️ORR: 0% CR, 1% PR, 10% MR, 83% SD ▶️23% grade ≥3 tox (mostly ↑ LFTs) ▶️Never compared to RT+PCV/TMZ - only placebo ▶️Cross-over allowed (placebo patients were deprived standard of therapy chemoRT twice [at randomization, and at progression] ▶️82% placebo patients progressed at 2 years (these patients should NOT have been observed in the first place) ▶️Short follow-up (14 mo.) RT toxicities in LGGs often overstated, especially in the context of modern RT techniques (IMRT, VMAT, protons): 🔷️Radiation necrosis ~2% 🔷️Absolute risk of stroke is exceedingly low 🔷️Hormone dysfunction only with significant hypothalamic/pituitary dose (and is a fixable issue); uncommon with modern conformal RT 🔷️Prospective cognitive studies: most show no sustained decline; when seen, often due to tumor progression, not RT 👉 Painting RT as a toxic treatment for LGGs while overselling modest to negligible INDIGO results is misleading for patients and physicians #ASTRO25 #RadOnc #NeuroOnc
Stanislav (Stas) Lazarev, MD tweet mediaStanislav (Stas) Lazarev, MD tweet mediaStanislav (Stas) Lazarev, MD tweet mediaStanislav (Stas) Lazarev, MD tweet media
English
1
16
58
3.5K
Nadia Laack, MD MS
Nadia Laack, MD MS@n_laack·
Looking forward to connecting with our alumni at ASTRO - check your emails and register!
Nadia Laack, MD MS tweet media
English
0
3
12
737
Nadia Laack, MD MS retweetledi
PDBrown
PDBrown@PDBrownOnc·
25-year Cohort Study SRS sporadic meningioma · 653 tumors SRS · Median volume & margin dose 4.5 cc & 15 Gy · In-field & marginal progression 1.1% & 0.3% · 10 Yr PFS 99% journals.lww.com/neurosurgery/a…
English
2
9
41
3.2K

Keşfet

@MayoClinic @Merck @SamirPatelMD @MayoCancerCare @MayoRadOnc @MDAndersonnews @lauren_henke @APrice_BeamOn